Live from the NIH registry
Studies recruiting near Eugene right now
Top 25 of 144 recruiting studies, sorted by proximity — each links to its official registry page
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center) — Eugene, Oregon (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 270 participants sought
517 — Eugene, Oregon (1.6 mi)
· Sponsor: Corcept Therapeutics
Adaptation of the Family Check-Up Online
Substance Use (Drugs, Alcohol)
N/A
Interventional 108 participants sought
University of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: University of Oregon
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Phase 2, Phase 3
Interventional 268 participants sought
Oncology Associates of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: Kartos Therapeutics, Inc.
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 3
Interventional 700 participants sought
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon (1.6 mi)
· Sponsor: Janssen Research & Development, LLC
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
Keratoconus, Unstable, Bacterial Keratitis
Phase 1
Interventional 300 participants sought
Pacific Clear Vision Institute — Eugene, Oregon (1.6 mi)
· Sponsor: Pacific Clear Vision Institute
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Phase 1, Phase 2
Interventional 952 participants sought
USOR Oncology Associates of Oregon, P.C. — Eugene, Oregon (1.6 mi)
· Sponsor: Genmab
C-Protein in Fatigue and Aging
Aging, Muscle Atrophy or Weakness
N/A
Interventional 24 participants sought
University of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: University of Oregon
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis
N/A
Interventional 150 participants sought
Pacific Sports & Spine — Eugene, Oregon (1.6 mi)
· Sponsor: Spinal Simplicity LLC
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma (MM), Multiple Myeloma Refractory
Phase 2
Interventional 46 participants sought
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Phase 2, Phase 3
Interventional 690 participants sought
Oncology Associates Of Oregon, Pc — Eugene, Oregon (1.6 mi)
· Sponsor: Bristol-Myers Squibb
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
Phase 1, Phase 2
Interventional 330 participants sought
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon (1.6 mi)
· Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Phase 3
Interventional 531 participants sought
Willamette Valley Cancer Institute and Research Center /ID# 280617 — Eugene, Oregon (1.6 mi)
· Sponsor: AbbVie
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Phase 2
Interventional 250 participants sought
Oncology Associates of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: Allogene Therapeutics
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
Verum Research, LLC — Eugene, Oregon (1.6 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Chronic Low-back Pain, Vertebrogenic Pain Syndrome
N/A
Observational 1,500 participants sought
Pacific Sports and Spine — Eugene, Oregon (1.6 mi)
· Sponsor: Boston Scientific Corporation
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Phase 3
Interventional 500 participants sought
Oncology Associates of Oregon Willamette Valley Cancer Center — Eugene, Oregon (1.6 mi)
· Sponsor: BeOne Medicines
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 850 participants sought
Oncology Associates Of Oregon, Pc — Eugene, Oregon (1.6 mi)
· Sponsor: Bristol-Myers Squibb
Garden-fresh Foods and Gut Microbiomes
Gut Microbiome
N/A
Interventional 20 participants sought
Institute for Health in the Built Environment, University of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: University of Oregon
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Substance Abuse, Decision Making, Shared
N/A
Interventional 341 participants sought
Chestnut Health Systems — Eugene, Oregon (1.6 mi)
· Sponsor: Chestnut Health Systems
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 140 participants sought
Oncology Associates of Oregon, P.C. /ID# 275006 — Eugene, Oregon (1.6 mi)
· Sponsor: AbbVie
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-Small Cell Lung Cancer
Phase 3
Interventional 1,600 participants sought
Willamette Valley Cancer Institute and Research Center (WVCI) — Eugene, Oregon (1.6 mi)
· Sponsor: Summit Therapeutics
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Multiple Myeloma
Phase 2
Interventional 100 participants sought
Oncology Associates of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
CLL, Chronic Lymphocytic Leukemia
Phase 3
Interventional 250 participants sought
Oncology Associates of Oregon Willamette Valley Cancer Center — Eugene, Oregon (1.6 mi)
· Sponsor: BeOne Medicines
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
Degenerative Disc Disease
Phase 3
Interventional 162 participants sought
Pacific Sports and Spine — Eugene, Oregon (1.6 mi)
· Sponsor: DiscGenics, Inc.